These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38695730)

  • 1. Regulation of RAF family kinases: new insights from recent structural and biochemical studies.
    Spencer-Smith R; Morrison DK
    Biochem Soc Trans; 2024 Jun; 52(3):1061-1069. PubMed ID: 38695730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
    Rebocho AP; Marais R
    Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP90-CDC37-PP5 forms a structural platform for kinase dephosphorylation.
    Oberoi J; Guiu XA; Outwin EA; Schellenberger P; Roumeliotis TI; Choudhary JS; Pearl LH
    Nat Commun; 2022 Nov; 13(1):7343. PubMed ID: 36446791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites.
    Eckl JM; Scherr MJ; Freiburger L; Daake MA; Sattler M; Richter K
    J Biol Chem; 2015 Dec; 290(52):30843-54. PubMed ID: 26511315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding.
    Martinez Fiesco JA; Durrant DE; Morrison DK; Zhang P
    Nat Commun; 2022 Jan; 13(1):486. PubMed ID: 35078985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function.
    Grammatikakis N; Lin JH; Grammatikakis A; Tsichlis PN; Cochran BH
    Mol Cell Biol; 1999 Mar; 19(3):1661-72. PubMed ID: 10022854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleotide-Free sB-Raf is Preferentially Bound by Hsp90 and Cdc37 In Vitro.
    Eckl JM; Daake M; Schwartz S; Richter K
    J Mol Biol; 2016 Oct; 428(20):4185-4196. PubMed ID: 27620500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling from RAS to RAF: The Molecules and Their Mechanisms.
    Jeon H; Tkacik E; Eck MJ
    Annu Rev Biochem; 2024 Aug; 93(1):289-316. PubMed ID: 38316136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
    Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
    Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses of the oncogenic BRAF
    Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
    J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric activation of functionally asymmetric RAF kinase dimers.
    Hu J; Stites EC; Yu H; Germino EA; Meharena HS; Stork PJS; Kornev AP; Taylor SS; Shaw AS
    Cell; 2013 Aug; 154(5):1036-1046. PubMed ID: 23993095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of BRAF by CDC37 and Re-Evaluation of the Activation Mechanism for the Class 2 BRAF-L597R Mutant.
    Bjorklund DM; Morgan RML; Oberoi J; Day KLIM; Galliou PA; Prodromou C
    Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.
    Smith JR; de Billy E; Hobbs S; Powers M; Prodromou C; Pearl L; Clarke PA; Workman P
    Oncogene; 2015 Jan; 34(1):15-26. PubMed ID: 24292678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
    Monaco KA; Delach S; Yuan J; Mishina Y; Fordjour P; Labrot E; McKay D; Guo R; Higgins S; Wang HQ; Liang J; Bui K; Green J; Aspesi P; Ambrose J; Mapa F; Griner L; Jaskelioff M; Fuller J; Crawford K; Pardee G; Widger S; Hammerman PS; Engelman JA; Stuart DD; Cooke VG; Caponigro G
    Clin Cancer Res; 2021 Apr; 27(7):2061-2073. PubMed ID: 33355204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
    Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
    Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37.
    Vaughan CK; Mollapour M; Smith JR; Truman A; Hu B; Good VM; Panaretou B; Neckers L; Clarke PA; Workman P; Piper PW; Prodromou C; Pearl LH
    Mol Cell; 2008 Sep; 31(6):886-95. PubMed ID: 18922470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.
    Yao Z; Gao Y; Su W; Yaeger R; Tao J; Na N; Zhang Y; Zhang C; Rymar A; Tao A; Timaul NM; Mcgriskin R; Outmezguine NA; Zhao H; Chang Q; Qeriqi B; Barbacid M; de Stanchina E; Hyman DM; Bollag G; Rosen N
    Nat Med; 2019 Feb; 25(2):284-291. PubMed ID: 30559419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
    Andreadi C; Cheung LK; Giblett S; Patel B; Jin H; Mercer K; Kamata T; Lee P; Williams A; McMahon M; Marais R; Pritchard C
    Genes Dev; 2012 Sep; 26(17):1945-58. PubMed ID: 22892241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.